Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-PD-1/LAG-3 bispecific antibody AK129

A humanized, immunoglobulin G1 (IgG1) bispecific antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PD1; PDCD1; CD279; programmed death 1) and lymphocyte activation gene 3 protein (LAG-3; LAG3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1/LAG-3 bispecific antibody AK129 targets and binds to both PD-1 and LAG-3 expressed on T cells, thereby blocking the interaction of PD-1 to its ligand programmed cell death-ligand 1 (PD-L1; cluster of differentiation 274; CD274) and of LAG-3 to its ligand major histocompatibility complex II (MHCII). This inhibits the PD-1- and LAG-3-mediated downregulation of T-cell activation and proliferation and abrogates downstream immune suppression. This may lead to a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. PD-1 and LAG-3 play key roles in suppressing T-cell activation and proliferation and promote tumor immune escape.
Synonym:PD-1 x LAG-3 bispecific antibody AK129
Code name:AK 129
AK-129
AK129
Search NCI's Drug Dictionary